8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 5, 2014

Quest Diagnostics Incorporated

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or other jurisdiction of Incorporation)

001-12215	16-1387862
(Commission File Number)	(I.R.S. Employer Identification No.)
Three Giralda Farms Madison, NJ 07940	07940
(Address of principal executive offices)	(Zip Code)
(973) 520-2700
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the exchange Act (17 CFR 240.13e-4(c))

Item 7.01    Regulation FD Disclosure

On November 5, 2014, Quest Diagnostics Incorporated (the “Company”) hosted an investor meeting (“Investor Day”) at which management presented its views regarding, among other things, the industry and the Company’s strategy and plans to drive shareholder value. The Investor Day presentation materials are attached hereto as Exhibits 99.1 - 99.8 and are incorporated herein by reference.

In connection with Investor Day, the Company issued a press release on November 5, 2014, announcing, among other things, the following:

• The Company expects to generate an additional $600 million in run-rate savings from the Invigorate initiative during the three year period ended December 31, 2017, and exit 2017 with total run-rate savings of $1.3 billion from the Invigorate initiative. Previously, the Company announced that it expected to exit 2014 with run-rate savings of $700 million from the Invigorate initiative.

• The Company announced expected annual growth in revenues and earnings per share during the three-year period ending December 31, 2017.

• Beginning in 2015, the Company intends to report financial results, and provide guidance regarding financial results, on the following basis: “adjusted diluted EPS”, excluding the impact of amortization charges. The Company estimates full year 2014 amortization charges will be approximately $0.40 per diluted share.

• The Company reiterated its expectations for 2014 results from continuing operations before special items.

A copy of the press release is attached hereto as Exhibit 99.9 and is incorporated by reference herein.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1- 99.9, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01 Financial Statements and Exhibits

d.	Exhibit	Description
	99.1	Investor Day presentation, dated November 5, 2014, entitled “Our Path Forward,” presented by Steve Rusckowski, President and Chief Executive Officer
	99.2	Investor Day presentation, dated November 5, 2014, entitled “Reinventing the Lab Test,” presented by Jay Wohlgemuth, M.D., Senior Vice President, Medical, Science and Innovation
	99.3	Investor Day presentation, dated November 5, 2014, entitled “Driving Operational Excellence,” presented by Jim Davis, Senior Vice President, Operations
	99.4	Investor Day presentation, dated November 5, 2014, entitled “Building Our Clinical Franchises,” presented by Cathy Doherty, Senior Vice President, Clinical Franchise Solutions

99.5	Investor Day presentation, dated November 5, 2014, entitled “Accelerating Growth,” presented by Everett Cunningham, Senior Vice President, Commercial
99.6	Investor Day presentation, dated November 5, 2014, entitled “Cancer Genetics and Professional Laboratory Services,” presented by Jon Cohen, M.D., Senior Vice President and Group Executive, Diagnostics Solutions, Chief Medical Officer
99.7	Investor Day presentation, dated November 5, 2014, entitled “Delivering a Platform for Growth,” presented by Lidia Fonseca, Senior Vice President, Chief Information Officer
99.8	Investor Day presentation, dated November 5, 2014, entitled “Capital Plan: Delivering and Returning Value,” presented by Mark Guinan, Senior Vice President, Chief Financial Officer
99.9	Press release of the Company, dated November 5, 2014

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

November 5, 2014

QUEST DIAGNOSTICS INCORPORATED

By:    /s/ William J. O’Shaughnessy, Jr.

William J. O’Shaughnessy, Jr.

Deputy General Counsel and Secretary

EX-99.1

Our Path Forward Steve Rusckowski President and Chief Executive Officer November 5th, 2014

| 2 Safe Harbor Disclosure The statements in this presentation which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

| 3 Empowering Better Health with Diagnostic Insights

| 4 Delivering on Investor Day 2012 Commitments DRIVE SIMPLIFY RESTORE REFOCUS DELIVER $700M RUN-RATE SAVINGS EXPECTED 1 UNIFIED TEAM 3 FEWER LAYERS ~3.5% EXPECTED GROWTH IN 2014 $800M RETURNED P R O C E E D S FROM ASSET S A L E S >$1B THROUGH SHARE REPURCHASES 7 ACQUISITIONS $1B SINCE 2011 & DIVIDENDS INVESTED IN

| 5 Our New Team Steve Rusckowski President & CEO Jon Cohen MD SVP & Group Executive Diagnostic Solutions, Chief Medical Officer Everett Cunningham SVP Commercial Jim Davis SVP Operations Dermot Shorten VP Strategy & Ventures Tim Sharpe VP Compliance Gary Samuels VP Communications John Haydon VP Joint Ventures and Strategic Programs Mike Prevoznik General Counsel & SVP International Mark Guinan SVP & CFO Jeff Shuman SVP Chief Human Resources Lidia Fonseca SVP & Chief Information Officer Cathy Doherty SVP & Group Executive Clinical Franchise Solutions Jay Wohlgemuth MD SVP Medical, Science and Innovation

| 6 Quest is the Clear Leader in a Fragmented Market Total U.S. Lab Market “Outside the Hospital” Lab Segment Independent Lab Segment 10% DGX Hospital Outpatient Hospital Inpatient 39% Independent Labs 14% 35% Hospital Outreach POL 6% Other 6% 37% Small Independent Labs 26% 20% LCA Niche Labs 9% Tier 2 Labs 8% 17% 21% 52% Outside the Hospital $75 BILLION $46 BILLION $25 BILLION DGX DGX

| 7 • ACA Lives • Population • Demographics • Esoteric Utilization • Government and Commercial Reimbursement Pressure • Shifting from FFS to Bundled Payments • Growth in Exchanges and Medicaid Reimbursement • Hospital Consolidation • New Models / ACO • Changing Benefit Design • Preventive Care • Pricing Transparency Stakeholder Dynamics • Advances in Genomics • Precision Medicine • Clinical Decision Support • Population Health Technology Evolution Market Drivers and Dynamics Quest is Positioned for Continued Market Leadership During a Time of Significant Change

| 8 The Market Outside the Hospital is Growing 3-4% 39% Independent Labs 14% 35% Hospital Outreach POL 6% Other 6% $46 BILLION Growing 3-4% DGX GROWING 4% Hospital Outreach GROWING 2-3% $25B Independent Labs

| 9 Size & Scale High Value Provider Innovation & Insights Quest is Well Positioned to Grow

| 10 Unmatched Size and Scale Will Benefit Quest SERVES IN >$7B REVENUE 50% OF HOSPITALS SERVES 1/3 OF THE U.S. ADULT POPULATION AND WITHIN ~50% 3 YEARS 2,000 PATIENT SERVICE CENTERS >200K Care360 PLACEMENTS >25 MAJOR TESTING SITES 3,500 COURIERS 10,000 PHLEBOTOMISTS, PARAMEDICS, & CONTRACT NURSES, IOPs TEST RESULTS >20B DELIVERED OVER PAST DECADE

| 11 “Outrageous” blood work bill from Queen of the Valley hospital gives small biz owner pain in neck Greater Pricing Transparency Favors Quest as High-Value Provider Media Focus on Disparities in Healthcare Costs Quest Offers 2-5X Value vs. Hospital and Specialty Boutique Competitors Patients with High Deductible Plans are More Price Sensitive – JAMA, 2014

| 12 Innovation and Insights Enhance Customer Engagement 1st TO OFFER ONLINE ORDER ENTRY & RESULTING SYSTEM 1st TO OFFER PATIENT APPOINTMENT SCHEDULING 1st TO OFFER PATIENT MOBILE APPLICATION INTERACTIVE INSIGHTS PATIENT-PHYSICIAN COORDINATED INSIGHTS

| 13 Our Strategy Refocus on Diagnostic Information Services 4 Simplify the Organization 3 Drive Operational Excellence 2 Restore Growth 1 Deliver Disciplined Capital Deployment 5 REFOCUS SIMPLIFY DRIVE RESTORE DELIVER

| 14 Commercial Excellence Clinical-Based Focus to Grow Esoteric Testing Partnering with Hospitals Near Term Focus 1 RESTORE

| 15 Longer Term Focus 1 RESTORE Succeed Internationally Leverage Capabilities into Extended Care Settings Create Value from Information Assets Lead in Precision Medicine

| 16 Superior Customer Experience Cost Excellence Drive Operational Excellence 2 DRIVE IN RUN RATE SAVINGS $1.3B THROUGH 2017

| 17 Simplify the Organization 3 SIMPLIFY Continue to Strengthen Team Building a High Performance Culture

| 18 Refocus on Diagnostic Information Services 4 REFOCUS $800M in Proceeds from 4 Divestitures Sharp Focus on Core

| 19 Deliver Disciplined Capital Deployment 5 DELIVER Returning Majority of Free Cash Flow to Shareholders Investing in the Business Value Creating M&A

| 20 Key Takeaways We did what we said we’d do Clearly focused on opportunities in our core diagnostic information services business Driving a superior customer experience and boosting efficiency Delivering disciplined capital deployment Well positioned to grow and continue to lead

EX-99.2

Reinventing the Lab Test Jay Wohlgemuth, M.D. Senior Vice President, Medical, Science and Innovation November 5th, 2014

| 2 Safe Harbor Disclosure The statements in this presentation which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

| 3 Entering The Era of Precision Medicine DELIVERING EFFECTIVE CARE TO THE RIGHT POPULATIONS AND INDIVIDUALS THROUGH COMPREHENSIVE SOLUTIONS PRECISION MEDICINE IS A RAPIDLY GROWING MULTI-BILLION DOLLAR MARKET TODAY WITH ACCELERATION IN ADOPTION AND NEW APPLICATIONS

| 4 Quest is Uniquely Positioned to Lead in Precision Medicine INSIGHTS DISEASE BASED CLINICAL FOCUS Precision Medicine with Actionable Insights Advanced Technologies Big Data Collaborations Comprehensive Solutions

| 5 Patient Continuum of Care Clinical Franchise Cardiovascular Advanced Lipid Fractions Comprehensive Solutions – Evidence Based Medicine PRIMARY CARE ROUTINE SPECIALIST ESOTERIC Lipid Panel Dementia HCV Genetics & Biomarkers Memory Loss Diagnostics Viral Genomic Testing Screening CLINICAL FOCUS It Starts with a Clinical Focus on a Specific Disease State or Clinical Problem

| 6 Advanced Sequencing and Molecular Miniaturization and Sample Innovations Bioinformatics and IT Mass Spectrometry and Proteomics ADVANCED TECH Advanced Technology is Enabling Solutions to Key Clinical Problems

| 7 >20B test results BIG DATA We are Using Our Big Data to Help Manage Populations and Target Health Care Solutions PUBLISHED IN PRESTIGIOUS PEER REVIEWED JOURNALS

| 8 We are Working with World Class Healthcare Leaders to Make Precision Medicine a Reality PARTNERS

| 9 Delivering Comprehensive Solutions COMPREHENSIVE SOLUTIONS

| 10 Advanced Technologies Big Data Collaborations Case Study: Developing a Comprehensive HCV Solution to Help Manage a Significant Public Health Threat INSIGHTS Hepatitis C screening guidelines for >78M in US and availability of highly efficacious therapies Rapid adoption and growth of HCV care diagnostic solutions Comprehensive Solutions CLINICAL FOCUS

| 11 Key Takeaways Data-driven insights making precision medicine a reality Applying advanced technology for more precise, comprehensive and useful information “Big Data” analytics target effective solutions to the right populations Partnering with world-class thought leaders Moving from selling “a test” to offering “comprehensive solutions”

EX-99.3

Driving Operational Excellence Jim Davis Senior Vice President, Operations November 5th, 2014

| 2 Safe Harbor Disclosure The statements in this presentation which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

| 3 Cost Excellence Driving Operational Excellence Organization Information Technology Billing Laboratory Procurement Service Delivery Superior Customer Experience Analytic Transparent Seamless Convenient

| 4 6 Flagship Programs Opportunity Targeted Run Rate Organization Excellence Simplify organization structure & reduce management layers $80M IT Excellence Standardize & simplify systems & reduce fixed costs $65M Procurement Excellence Reduce unit cost & improve total cost of ownership $150M Service Excellence Automate processes & leverage scale across enterprise $65M Lab Excellence Optimize capacity & facility footprint, automate processes & apply lean manufacturing principles $150M Billing Excellence Reduce bad debt & improve collections efficiency $90M TOTAL $600M Invigorate’s 6 Flagship Programs all Drove Significant Savings and Improved Performance Across the Customer Value Chain 1 2 3 4 5 6

| 5 $200 $500 $700 2012 2013 2014F Delivering Run-Rate Savings $’s in Millions Track Record of Cost Excellence 6 Flagship Programs Organization Excellence IT Excellence Procurement Excellence Service Excellence Lab Excellence Billing Excellence

| 6 Converge 22,000 sqft Cambridge 130,000 sqft Athena 32,000 sqft UMass 50,000 sqft Wallingford 87,000 sqft TOTAL 321,000 SQ FT Building the Lab of the Future to Serve New England

| 7 Building the Lab of the Future to Serve New England Cost Per Test Converge 22,000 sqft Cambridge 130,000 sqft Athena 32,000 sqft UMass 50,000 sqft Wallingford 87,000 sqft Quality TOTAL 204,000 SQ FT REDUCTION 36% MARLBOROUGH LAB

| 8 61 CENTERS 41 SYSTEMS 4,272 FTEs 16 38 3,112 74% 7% 27% 2011 2014 Centralized into National Centers in Kansas, Florida and Pennsylvania Standardizing and enhancing tools and technology Benefitting from increased self-service tools Consolidated Contact Centers Improve Quality and Efficiency

| 9 Supply Chain Management $25M Platform Standardization Women’s Health HIV Auto-Chemistry $60M Pre-Analytic Consumables Standard Specification SKU Reduction Global Sourcing Supplier Engagement Design Feedback Reliability and Uptime Reagent Utilization 20 Suppliers 6 Summits 2 Development Programs

| 10 Identifying Key Opportunities to Meet our New $600M Goal $600M • Process • Data • Systems Standardizing the Model • eOrder • eBill • ePickup • eCare • eResult eEnabling Services • ezPay • Notification • Open Balance • Upfront Payment • Convenient Options Getting Paid for What We Do Changing How We Operate

| 11 Standardization of Process, Information Technology and Equipment Seamless Flow From Patient Draw To Final Result Enabled by Standard Systems, Technology and Process Information & Data Multiple Lab Systems Limits ability to move specimens Disconnected client, test and patient data Standardize Enterprise core platform One Operational Data View to serve Internal and External needs Equipment & Platforms Automation and Testing Ten largest labs at various levels of automation Limits scale and standardization Standard Platform, Full Automation Expand robotic solutions to take full advantage of scale as we consolidate Process & Workflow Non-Standard Workflow Multiple Lab systems and workflows increase complexity of draw and labeling down to the test tube level Standard Workflow, Common Supplies Redesign process around standard systems and automation and extend into client workflow

| 12 eEnablement Brings Convenience, Quality and Efficiency Too Many! Paper Orders >15k Pickup Calls >15k Results Calls >5M Pages Printed/Faxed Too High! Invoicing Costs

| 13 Getting Paid for What We Do Today Test Ordering Payment for Service New Test Introduction Tomorrow Uncertain medical coverage Uncertainty on patient payment Known medical coverage Patient acknowledgment to pay Voluntary upfront payments Estimated charges Real-time adjudication Payment at time of service Miscellaneous codes Undefined payer policies Uncertain payments Defined coding Positive medical coverage Value-based payments

| 14 Building a Superior Customer Experience & Lowering Cost Organization Information Technology Billing Laboratory Procurement Service Delivery Cost Excellence $600M Over Three Years Superior Customer Experience Analytic Transparent Seamless Convenient

| 15 Key Takeaways Track record of cost excellence Prior focus was on consolidating footprint and supply chain management Future focus on standardization and e-enablement Building a superior customer experience and lowering cost

EX-99.4

Building Our Clinical Franchises Cathy Doherty Senior Vice President & Group Executive Clinical Franchise Solutions November 5th, 2014

| 2 Safe Harbor Disclosure The statements in this presentation which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

| 3 Clinical Franchise Science & Innovation Value Creation

| 4 General Health & Wellness Cardiovascular, Metabolic & Endo Infectious Disease/ Immunology Neurology Women’s and Reproductive Health Prescription Drug Monitoring/ Toxicology Cancer Diagnostics Clinical Franchises Organized by Disease/Health State 2 3 4 5 6 1 7 Sports Diagnostics 8

| 5 Case Study #1: Prescription Drug Monitoring 2009 2010 2011 2012 2013 Market Size $2 billion annually; growing double digits. Estimated 100M Americans are in pain; 259M painkiller prescriptions written in 2013 Market Need Help physicians manage prescription drug abuse, misuse, and non-use by monitoring patient compliance with prescriptions Respond to market interest, launch initial pilot program in 1 market Product launches in >80% of markets with Enhanced MedMatch Report National Roll Out complete Create franchise to support business with dedicated general manager and sales specialists Quest Diagnostics Health Trends Report on Prescription Drug Misuse in America

| 6 Prescription Monitoring Program Enables Physicians and Public Health Authorities to Improve Patient Compliance

| 7 Acquire Summit Health and launch 2nd generation insight driven participant reports Establish Wellness as a critical strategic priority Case Study #2: Health & Wellness Present our first Wellness ROI study at AJHP Launch finger stick solution for worksite clinics & expand biometric capability to 2k patient service centers Publish PLoS One study and add “Gap in Care” capability Blueprint for Wellness screens more than 1 million employees 1st client with >100k employees screened 2009 2010 2011 2012 2013 2014 Market Size Worksite Wellness Screening market $2B annually; growing double digits Market Need Help employers and their employees manage their health using routine tests to identify health risks early when preventive action can be taken

| 8 Key Takeaways Clinical Franchises have helped us deliver new solutions Demonstrated ability to grow organically Tapping rapidly growing market segments Expanding pipeline of innovative new solutions awaiting launch

EX-99.5

Accelerating Growth Everett Cunningham Senior Vice President, Commercial November 5th, 2014

| 2 Safe Harbor Disclosure The statements in this presentation which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

| 3 The Commercial Organization has Come a Long Way in 2 Years INVESTOR 2014 D A Y 1 Unified Sales Team • Attracting talent • Reduced turnover • Enhanced growth culture

| 4 Keys to Success One Sales Organization, Focused on Local Customers Needs #1 All Healthcare is Local… 8 regional leaders 108 aligned districts • Sales Director/GM • Specialty Rep Focus • Clinical Franchise Solutions • Customer & Market Focused National and local payer partnerships Improved execution One unified team WEST MIDWEST GREAT LAKES EAST NORTH SOUTHWEST SOUTH SOUTHEAST

| 5 Keys to Success Discipline around Processes, Tools and Measurement #2 Tools to Drive Effectiveness… Targeting high value opportunities Increase call frequency & impact Manage account relationships Enable call-point coordination Align field force with clinical franchises Manage performance

| 6 Keys to Success Focus on Talent Acquisition, Growth & Retention #3 A Winning Team… National Sales Meeting/Training Sustained training through online process Focus on specialty opportunities Integrity selling – single customer-focused methodology Performance driven culture

| 7 Engaging in the Market

| 8 Key Takeaways Focus on Growing Esoteric Lab Professional Services Superior Customer Experience The Commercial organization has come a long way in 2 years One sales organization: better led, staffed, equipped, trained, and motivated Resources being deployed against the best growth opportunities The new Quest is building momentum and continuing to make progress

EX-99.6

Cancer Genetics & Professional Laboratory Services Jon Cohen, MD Senior Vice President and Group Executive Diagnostic Solutions, Chief Medical Officer November 5th, 2014

| 2 Safe Harbor Disclosure The statements in this presentation which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

| 3 Cancer Genetics Assessing Risk Breast & Ovarian Colorectal & Endometrial BRCAvantage™ Guiding Treatment Solid Tumor Leukemia OncoVantage™

| 4 BRCAvantage™: Assessing Risk of Breast and Ovarian Cancer Market Overview and Trends 940,000 people in the US carry the BRCA gene 2.3M at high risk and should be screened $3B market

| 5 BRCAvantage™: Insights and Services Concierge & Preauthorization Services Women’s Health, Primary Care, Hospital, and Oncology Sales Teams BRCAvantage™ Plus 7 Gene Expanded Breast Cancer Panel Specialized Medical Oncology Sales Team Patient Awareness Advocacy Financial Assistance Genetic Counseling

| 6 OncoVantage™: Guiding Cancer Treatment Market Overview and Trends 1.6M new cancer cases each year 1.2M estimated patients with failed therapy $1.3B is underpenetrated approximately

| 7 OncoVantage™ Guiding Treatment Memorial Sloan Kettering Cancer Center and Quest Diagnostics Partner to Advance Precision Medicine in Cancer Diagnosis and Treatment Diagnostic insights into gene mutations in solid tumor cancers will aid therapy selection and prognosis for patients and advance research Jun 1, 2014 NEW YORK and MADISON, N.J., June 1, 2014 /PRNewswire/ -- Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center, and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a joint collaboration that will utilize MSK's clinical and research insights into gene mutations associated with solid tumors. The goal is to use molecular laboratory testing to improve physicians' ability to treat patients with breast, prostate, colon, lung, and a variety of other solid tumor cancers by giving them a better understanding of the genomic underpinnings of their patients' illnesses.

Professional Lab Services | 8

| 9 Hospital and Hospital System Business Solutions Level of Strategic Partnership Reference Testing Options Managed Labs Options V alue C re atio n Outreach Solutions Population Management Utilization Management Improve Inpatient Experience Clinical Franchise Solutions Increase Patient Stickiness Reference Testing Expanded Reference Supply Chain Management Managed Labs Joint Venture

| 10 PLS Strategic Relationships Client State Number of Hospitals Number of Beds Safety Net Illinois 1 125 Rural New York 1 100 Community Connecticut 1 200 Health System Alabama 4 956 Community Pennsylvania 1 200 Health System New Jersey 4 1250 A Track Record of Success

| 11 Key Takeaways Aggressively pursuing the growing market for cancer genetics Successfully launched and enhanced BRCAvantage solution Partnered with world’s premier cancer institution to reach community oncologists Leveraging Quest assets to deepen relationships with hospital clients New professional lab services business demonstrates ability to grow organically

EX-99.7

Delivering a Platform for Growth Lidia Fonseca Senior Vice President, Chief Information Officer November 5th, 2014

| 2 Safe Harbor Disclosure The statements in this presentation which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

| 3 Transforming Our Network Creates Value & Drives Growth Creating Value Integrated and efficient network Actionable insights Personalized experiences Growth Platform Insights empower providers Solutions enable patient engagement Embedded clinical and reimbursement guidelines

| 4 Building a Superior Customer Experience & Lowering Cost Integrated Delivery Network Cost Excellence Superior Customer Experience Personalized Experience Insights for Improved Outcomes • A Unified Quest • Standard Processes, Platforms & Data • Access • Convenience • Ease of Use • Analytics that Empower Better Health

| 5 Building an Integrated Network for the Future Current State Future State Business Processes Standard 70% Business Processes Simplified and Standardized 100% Master Data Siloed Encounter-Centric IT Systems Redundant, Complex 70% Master Data Single Source Patient-Centric IT Systems Rationalized, Integrated Common Platforms 100%

| 6 Personalized Experience Interactive InsightsTM Provider • Result Reports with Insights • Interactive Reporting • Physician View • Patient View • Tailored Report Formats

| 7 Personalized Experience MyQuestTM Patients • Access lab results • Trend results over time • Track conditions & allergies

| 8 Insights that Improve Outcomes Population Health Solutions • Identify & Monitor Risk • Track Lab Outcomes • Target Gaps in Care • Clinical Performance Benchmarks

| 9 Insights that Improve Outcomes Quest Analytics Platform Comprehensive Analytics • Aggregated Information Across the Clinical Record • Set specific goals • Drill down capabilities • Provider Benchmarks

| 10 Actionable Insights Enable Quest to Capture More Value Clinical and Financial Content Aggregation & Reporting, Pre-authorization services, Risk Management Solutions Lab Orders and Results Dif fe re n ti ato r Advanced Analytics Population Health, Quality Metrics, Gaps in Care, Utilization Management Clinical Pathways – Disease Management, Clinical Decision Support EMR Interfacing Lab Results / Reporting Lab Orders Basic Services Differentiated Insights

| 11 Key Takeaways Integrated network will drive efficiency and savings Population Health solutions and Interactive Insights empower providers Personalized experiences engage patients and improve outcomes Standard processes, data and systems create a superior customer experience We have the experience and innovation track record to get this done!

EX-99.8

Capital Plan: Delivering and Returning Value Mark Guinan Senior Vice President and Chief Financial Officer November 5th, 2014

| 2 Safe Harbor Disclosure The statements in this presentation which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

| 3 Consistent Structure to Our Plan Underpinning Capital Structure Return Majority of FCF to Investors Incremental Returns to Shareholders Operational Excellence Restore Growth Investments in Growth Committed Deployment Discretionary • Enabler of shareholder value creation • Maintain “strong BBB” investment grade credit rating • Superior Customer Experience • Cost Excellence • Tools to support commercial excellence • Diagnostic innovation: licensing, collaborations and internal development to grow esoteric testing • Maintain meaningful dividend, which can grow over time • Supplement with share repurchases • Value-creating acquisitions • Disciplined evaluation criteria • Additional share repurchases from free cash flow and potential portfolio actions

| 4 -8.0% -6.0% -4.0% -2.0% 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% Delivering Gradual Topline Improvement 2013 2012 2014 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Revenue Volume

| 5 -6.0% -5.0% -4.0% -3.0% -2.0% -1.0% 0.0% 1.0% 2.0% Delivering Gradual Topline Improvement Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2013 2012 2014 • Prescription Drug Monitoring • Health & Wellness • Infectious Disease • Anatomic Pathology Adjusted Organic Volume Organic Volume

| 6 Expectation of Reimbursement Pressure 3% 2013 <1% 2014 2012 Projection of 1-2% Over a 3-Year Period: 2013 - 2015 We expect reimbursement pressure to continue to be moderate between 2015 - 2017 YTD

| 7 Investing in Growth: $1B on 7 acquisitions Guidelines for Assessing Acquisitions Regional Independent Labs Specialty, Boutique Labs Hospital Outreach Converge Solstas ATN (Toxicology) Summit (Wellness) UMass Dignity Steward 2013 - 2014 Acquisitions Strategic Fit NPV ROIC EPS

| 8 Invigorate Savings $- $100 $200 $300 $400 $500 $600 $700 $800 2012 2013 2014 EST ORIGINAL 2011 TARGET TARGET SHARED IN 2012 We achieved our original Phase 1 target a year early and will exceed our revised target by $100 million Run Rate Realized Savings 2017 $1.3B New Target $’s in Millions

| 9 Invigorate has Delivered Savings to Offset Recent Headwinds SAVINGS OFFSETS Reimbursement Pressure Wage Inflation Fund Incentive Comp Modest Investments to Restore Growth

| 10 $- $200 $400 $600 $800 $1,000 $1,200 2013 2014 EST Meet or Exceed Our Commitments to Return Cash to Shareholders MAJORITY OF FREE CASH FLOW Return the Majority of Free Cash Flow to Shareholders through Dividends and Share Buybacks Share Buybacks • Repurchased >$1b of shares in past 2 years • Remaining authorization for share repurchases ~$750m Dividend • Increased 3x since 2011 Dividends Share Buybacks Free Cash Flow $’s in Millions

| 11 Report & Guide on “Cash EPS” in 2015 • Cash EPS = Adjusted Diluted EPS excluding amortization • Consistent with other healthcare companies and largest competitor • Continued investment community interest • Aid assessment of our M&A strategy • Amortization estimated to be ~$0.40 per diluted share for full year 2014 $0.09 Q1 $0.11 Q2 $0.10 Q3

| 12 MODERATE PRESSURE IMPROVING FEWER HEADWINDS REIMBURSEMENT UTILIZATION INVIGORATE Making Progress in an Improving Environment

| 13 Outlook 2014 FY Guidance 3-Year CAGR Revenue Increase of ~3.5% 2% to 5% • Includes M&A • Organic growth to accelerate to market levels through period Adjusted Diluted EPS $4.03 - $4.07 8-10% • Excludes share repurchases Adjusted Diluted EPS, Excluding Amortization Coming in 2015 8-10% • Excludes share repurchases Cash from Operations ~$900 million High single digit growth

| 14 Key Takeaways Consistent capital structure Invigorate savings continue to be key source of value creation Organic volume and revenue performance continue to improve Commitment remains to return a majority of FCF through dividends & share buybacks

| 15 Non-GAAP Reconciliations Adjusted Diluted EPS: Low High Diluted earnings per common share 3.52$ 3.56$ Restructuring and integration charges (a) 0.41 0.41 Other (b) 0.10 0.10 Adjusted diluted EPS 4.03$ 4.07$ (b) Represents pre-tax costs of $19 million principally related to legal matters. (a) Represents pre-tax costs of $91 million primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating our business. 2014 Guidance Before Special Items 2014 Free Cash Flow: Guidance 2013 Net cash provided by operating activities 900.00$ 652.00$ Add: income tax payment associated with the sale of Ibrutinib royalty rights - 175 Less: capital expenditures (300) (231) Free cash flow 600.00$ 596.00$ Adjusted diluted EPS and free cash flow are presented because management believes those measures are useful adjuncts to reported results under accounting principles generally accepted in the United States. Adjusted diluted EPS and free cash flow should not be considered as an alternative to the corresponding measures determined under accounting principles generally accepted in the United States. Reconciliations of these non- GAAP measures to the most comparable GAAP measures are included in the tables on the left.

EX-99.9

Quest Diagnostics Discusses Progress in Executing Strategy to Drive Shareholder Value and Presents Outlook at Investor Day

- Company Expects to Generate 2% to 5% Revenue Growth and Adjusted Diluted EPS Growth of 8% to 10% on Average Over Next Three Years -

- New Target of $600 Million in Additional Run-Rate Savings Over Next Three Years Will Bring Total Run-Rate Savings Expected by End of 2017 to $1.3 billion -

NEW YORK, Nov. 5, 2014 /PRNewswire/ -- At a meeting with analysts and investors at its Investor Day here today, members of the senior management team of Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, plan to discuss the company's industry leadership position and the progress made in executing its strategy to drive shareholder value.  A live webcast of the meeting will be broadcast simultaneously beginning at 9 am ET.

Senior management team speakers including Steve Rusckowski, President and Chief Executive Officer, and Mark Guinan, Chief Financial Officer, will summarize Quest Diagnostics' significant achievements since November 2012, the date of the company's last Investor Day, including:

Restoring growth, including an expected 3.5% increase in revenues in 2014.

Enhancing efficiency and delivering an expected $700 million in run-rate savings exiting 2014 through the company's Invigorate program - exceeding its target.

Simplifying and strengthening the organization to drive growth and operational excellence.

Refocusing on Quest's core diagnostic information services business, generating $800 million in asset sale proceeds.

Returning cash to shareholders with over $1 billion in share repurchases, raising dividends three times

since 2011, and investing $1 billion in seven acquisitions in the past two years.

The presentations by Quest senior management will highlight the company's continued focus on opportunities in its core business and will emphasize the following:

Revenue growth: The company expects to continue to achieve sequential improvement in organic revenue growth, with overall average revenue growth of 2% to 5% over the next three years. This expected revenue growth includes potential acquisitions.

Cost savings: The company expects to deliver $600 million in additional total run-rate savings over the next three years, bringing the total run-rate savings expected at the end of 2017 to approximately $1.3 billion.  The company has identified key opportunities to meet this goal, including the standardization of processes, information technology and equipment, which also support the company's efforts to deliver a superior customer experience.    

Over the next three years, Quest expects to achieve 8% to 10% adjusted diluted EPS growth on average, excluding the benefit of share repurchases. 

In 2015, Quest intends to report financial results and provide guidance using adjusted diluted EPS excluding amortization, which is a commonly used metric by a number of industry peers.  The company estimates full year 2014 amortization charges will be approximately $0.40 per diluted share. Adjusted diluted EPS excluding amortization is expected to grow 8% to 10% on average over the next three years, excluding the benefit of share repurchases. 

Quest intends to continue to return the majority of the free cash flow it generates to shareholders through share repurchases and dividends.

"Quest Diagnostics successfully delivered on the commitments we made at our 2012 Investor Day, and our focused, disciplined strategy positions us to continue to be the diagnostic information services leader in a rapidly evolving healthcare environment," said Steve Rusckowski, President and Chief Executive Officer.  "We said in 2012 that it would take time to get back on our growth track. We have made good progress restoring growth, and have seen gradual improvement in underlying trends in utilization and reimbursement. By further enhancing our customers' experience and improving the efficiency of our operations, we expect to deliver 8% to 10% annual EPS growth and 2% to 5% annual revenue growth on average over the next three years."

Reaffirming Outlook for 2014

In the course of the meeting, Quest Diagnostics intends to reiterate its expectations from continuing operations for 2014, before special items, specifically:

Revenues expected to increase approximately 3.5% compared to the prior year;

Adjusted diluted EPS to be between $4.03 and $4.07;

Cash provided by operations to approximate $900 million; and

Capital expenditures to approximate $300 million.

Webcast Attendance

A live webcast of the event will be broadcast simultaneously on the Investor Relations page of the Quest Diagnostics website for all interested parties.  To access the webcast or a replay of the event, visit: www.QuestDiagnostics.com/investor.  The webcast will begin promptly at 9 am ET and conclude at 12:30 pm ET.  A replay will be available following the meeting.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic information services needed to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com.

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and  Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

Contacts:

Wendy Bost, Quest Diagnostics (Media): 973-520-2800

Dan Haemmerle, Quest Diagnostics (Investors): 973-520-2900